证券代码：300558 证券简称：贝达药业 公告编号：2025-018 贝达药业股份有限公司 第四届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长丁列明先生召集，会议通知于 2025 年 4 月 4 日以电 话、邮件等形式送达全体董事，董事会会议通知中包括会议的相关材料，同时列明 了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 4 月 16 日在公司杭州总部行政大楼会议室召开，采 取现场会议和电话会议结合的方式现场投票表决。 3、本次董事会应到 11 人，实际出席会议人数 11 人。 4、本次董事会由董事长丁列明先生主持，公司研发总裁兼首席医学官 LI MAO 先生、董事会秘书吴灵犀先生列席了本次会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律 法规和《贝达药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 二、董事会会议审议情况 1、会议审议并通过了《2024 年度总经理工作报告》 经审议，公司董事会通过了《2024 年 ...

Financial Performance - The company's operating revenue for 2024 reached ¥2,891,950,112.03, representing a 17.74% increase compared to ¥2,456,196,486.62 in 2023[16]. - Net profit attributable to shareholders for 2024 was ¥402,569,335.69, up 15.67% from ¥348,032,472.42 in 2023[16]. - The net profit after deducting non-recurring gains and losses was ¥409,834,141.43, a significant increase of 55.92% from ¥262,848,818.84 in 2023[16]. - The company's total assets at the end of 2024 amounted to ¥9,341,677,723.81, reflecting a 2.13% increase from ¥9,146,908,395.53 at the end of 2023[16]. - The weighted average return on equity for 2024 was 7.43%, an increase of 0.54% from 6.89% in 2023[16]. - The company reported a net cash flow from operating activities of ¥911,172,176.22, a slight decrease of 0.33% compared to ¥914,227,977.50 in 2023[16]. - The company achieved a revenue of 289,195.01 million yuan, representing a year-on-year growth of 17.74%[75]. - The net profit attributable to shareholders was 40,256.93 million yuan, an increase of 15.67% compared to the previous year[75]. - The net profit excluding non-recurring gains and losses was 40,983.41 million yuan, reflecting a significant growth of 55.92% year-on-year[75]. Research and Development - The company has established research centers in Beijing and Hangzhou to enhance its drug development capabilities[9]. - The company is focused on developing new drugs, particularly targeting oncology treatments, which are critical for its growth strategy[9]. - The company has launched five new drugs as of 2024, including the first innovative drug, EGFR-TKI Alectinib (brand name: Kaimena®), and ALK inhibitor Ensartinib (brand name: Beimana®) among others[39]. - The company has a robust revenue growth and cash flow driven by a "R&D - commercialization - reinvestment" cycle, ensuring orderly advancement of its R&D pipeline[40]. - The company’s R&D investment for the year reached 71,717.78 million yuan, accounting for 24.80% of total revenue[79]. - The company focuses on innovative drug development, having successfully developed 5 new drugs and established a robust product pipeline[69]. - The company has several ongoing clinical trials, including BPI-520105 for EGFR mutation-positive solid tumors, currently in Phase I[110]. - The company is advancing multiple clinical trials, including Balstilimab and Zalifrelimab for cervical cancer, both in Phase II[108]. Market and Industry Trends - The pharmaceutical industry in China saw a 3.4% increase in added value for large-scale pharmaceutical enterprises in 2024, indicating a recovery trend[26]. - The government has implemented various policies to support the pharmaceutical industry, including reforms in drug procurement and healthcare insurance, which are expected to enhance industry growth[27]. - The market share of innovative drugs in China's core hospitals increased from 21% in 2015 to 29% in 2024, indicating significant growth momentum[30]. - The proportion of First-in-Class new drugs rose from 12% in 2020 to 35% in 2024, reflecting a shift towards differentiated targets and innovative technologies[33]. - The global pharmaceutical market is projected to reach $1.7667 trillion by 2026 and $2.0694 trillion by 2030, presenting substantial opportunities for domestic pharmaceutical companies[35]. - The biopharmaceutical industry in China is transitioning from "follower" to "leader," with significant growth in targeted therapy and immunotherapy sectors[143]. Corporate Governance and Management - The company has a commitment to ensuring the accuracy and completeness of its financial reports, as stated by its management[5]. - The company has a dedicated investor relations team to facilitate communication with stakeholders[13]. - The company emphasizes talent development, with nearly 40 PhDs and several recognized as national and provincial leading talents, aiming to boost organizational efficiency and innovation[86]. - The company has established a complete business system with independent operations in research, production, and sales, ensuring no competition or unfair transactions with the controlling shareholder[173]. - The company maintains independent financial operations, with a dedicated finance department and no shared bank accounts with the controlling shareholder[175]. - The company has a robust governance structure that aligns with legal requirements, ensuring effective decision-making and risk management[172]. - The board of directors consists of 11 members, including 4 independent directors, and held 8 meetings, ensuring compliance with legal procedures[166]. Product Development and Approvals - The application for the first-line indication of Beimana was approved by the FDA in December 2024, with the EMA submission process officially initiated[40]. - The company’s drug "Kai Meina" is the first domestically developed small molecule oral EGFR-TKI lung cancer targeted therapy approved for postoperative adjuvant indications[46]. - "Fu Meina," a new drug for advanced renal cell carcinoma, achieved a median progression-free survival (PFS) of 10 months and an overall survival (OS) of 30.4 months in combination therapy[45]. - The company’s product "Bei Meina" is the first Chinese original drug included in the NCCN guidelines for ALK-positive advanced NSCLC, with a median progression-free survival of 41.5 months in the overall population[44]. - The company’s product Beimingna was included in the National Medical Insurance Directory, enhancing its market position[76]. - The company’s product, Saimina, has been included in the National Basic Medical Insurance Drug List for 2024, with sales of Kaimina and Beimina accounting for over 10% of the company's main business revenue[97]. Strategic Initiatives and Future Plans - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, based on a total of 418,485,885 shares[6]. - The company emphasizes the importance of risk awareness regarding market competition and new drug development in its future plans[6]. - The company plans to explore combination therapies with "Kai Meina" to expand patient populations and enhance clinical value[49]. - The company is actively expanding its product pipeline, with multiple innovative drug applications approved, including BPI-520105 and BPI-221351[79]. - The company is focusing on expanding its manufacturing capacity to support stable production and meet market demand[96]. - The company plans to use up to RMB 250 million of idle raised funds for temporary working capital, with a remaining balance of RMB 180 million as of December 31, 2024[132]. - The company aims to enhance market expansion and brand strengthening with the launch of products like Kangmeina and He Yuan's albumin project, focusing on seven products[146]. Risk Management and Challenges - The company acknowledges the high investment, long cycle, and low success rate associated with new drug development, which poses risks throughout the clinical development process[152]. - The company recognizes the risk of losing core technical personnel, which could hinder new drug development and market expansion efforts[154]. - To mitigate competition risks, the company plans to strengthen product market positioning, implement differentiated competition strategies, and enhance patient education through new media[151]. - The company is adapting to industry policy changes and focusing on effective participation in centralized procurement to mitigate risks related to market access and operational costs[156].

证券代码：300558 证券简称：贝达药业 公告编号：2025-022 贝达药业股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日召开第四 届董事会第二十二次会议，审议通过了《2024 年度利润分配预案》，并将该议案提 交公司 2024 年度股东大会审议，经公司股东大会审议通过后即可实施。现将 《2024 年度利润分配预案》的具体情况公告如下： 一、利润分配预案的基本情况 经立信会计师事务所（特殊普通合伙）审计，公司 2024 年度归属于母公司 所有者的净利润 402,569,335.69 元，其中母公司净利润为 552,320,827.05 元。根据 利润分配以合并报表和母公司报表中可供分配利润孰低的原则，公司当年实现的 可供股东分配的利润为 402,569,335.69 元，加上以前年度未分配利润 2,293,220,793.27 元，减去 2023 年度已分红 71,142,600.45 元，加上本期处置其他 权益工具投资直接计入 ...

贝达药业（300558）公告，2024年营业收入28.92亿元，同比增长17.74%。归属于上市公司股东的净利 润4.03亿元，同比增长15.67%。基本每股收益0.96元/股，同比增长15.66%。公司拟以4.18亿股为基数， 向全体股东每10股派发现金红利2元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增0 股。 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-017 贝达药业股份有限公司 关于股东股份质押变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）今日接到股东宁波凯铭投资管理合伙企业 （有限合伙）（以下简称"凯铭投资"）函告，获悉凯铭投资持有本公司的部分股份发生质 押变动，现将具体情况公告如下： 一、股东股份质押基本情况 1、凯铭投资质押股份延期购回情况 | 是否为控股股东或 第一大股东及其 | 本次延期 购回数量 | 占其所持 | 占公司总 | 是否为 | 质押起始日 质押到期日 | | 延期后质押 | 质权人 | 质押用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 一致行动人 | （股） | 股份比例 | 股本比例 | 限售股 | | | 到期日 | | | | 是 | 2,516,151 | 3.14% | 0.60% | 否 | 2024/3/13 | 2025/4/11 | 2026/3/11 | ...

贝达药业股份有限公司 关于股东股份质押变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300558 证券简称：贝达药业 公告编号：2025-016 贝达药业股份有限公司（以下简称"公司"）今日接到股东宁波凯铭投资管理合伙企业 （有限合伙）（以下简称"凯铭投资"）函告，获悉凯铭投资持有本公司的部分股份发生质 押变动，现将具体情况公告如下： 一、股东股份质押基本情况 1、凯铭投资股份解除质押情况 | 股东 | 是否为控股股东或 | 本次解除质押 | 占其所持 | 占公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 第一大股东及其 | | | 总股本 | 起始日 | 解除日期 | 质权人 | | 名称 | | 股份数量（股） | 股份比例 | | | | | | | 一致行动人 | | | 比例 | | | | | 凯铭投资 | 是 | 1,000,000 | 1.25% | 0.24% | 2023/9/26 | 2025/4/2 | 招商证券股份有限公司 | 1 ...

截至2025年4月1日 午间收盘，医药生物行业爆发，CRO、创新药方向领涨。中证500质量成长指数(930939)强势上涨1.16%，成分股贝达药业(300558)上涨 8.06%，特锐德(300001)上涨7.39%，西部超导(688122)上涨7.16%，惠泰医疗(688617)，华海药业(600521)等个股跟涨。500质量成长ETF(560500)上涨0.93%， 最新价报0.97元，盘中成交额已达241.09万元。（以上所列示股票为指数成份股，仅做示意不作为个股推荐。过往持仓情况不代表基金未来的投资方向，也 不代表具体的投资建议，投资方向、基金具体持仓可能发生变化。市场有风险，投资需谨慎。) 数据显示，截至2025年3月31日，中证500质量成长指数(930939)前十大权重股分别为赤峰黄金(600988)、九号公司(689009)、水晶光电(002273)、胜宏科技 (300476)、西部矿业(601168)、东阿阿胶(000423)、晶晨股份(688099)、恺英网络(002517)、神州泰岳(300002)、宏发股份(600885)，前十大权重股合计占比 24.26%。 | 股票代码 | 股票 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-015 贝达药业股份有限公司 关于股东股份质押变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）今日接到股东宁波凯铭投资管理合伙企业 （有限合伙）（以下简称"凯铭投资"）函告，获悉凯铭投资持有本公司的部分股份发生质 押变动，现将具体情况公告如下： 一、股东股份质押基本情况 1、凯铭投资股份新增质押情况 | | 是否为控 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 本次质押 | 占其所 | 占公司 | 是否为 | 是否为 | 质押 | 质押 | | 质押 | | 名称 | 第一大股 | 数量 | 持股份 | 总股本 | 限售股 | 补充质押 | 起始日 | 到期日 | 质权人 | 用途 | | | 东及其一 | （股） | 比例 | 比例 | | | | | | | | | 致行动人 | | ...

贝达药业股份有限公司 关于股东股份质押变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）今日接到股东宁波凯铭投资管理合伙企业 （有限合伙）（以下简称"凯铭投资"）函告，获悉凯铭投资持有本公司的部分股份发生质 押变动，现将具体情况公告如下： 一、股东股份质押基本情况 1、凯铭投资股份解除质押情况 | 股东 | 是否为控股股东或 第一大股东及其 | 本次解除质押 | 占其所持 | 占公司 总股本 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 股份数量（股） | 股份比例 | | | | | | | 一致行动人 | | | 比例 | | | | | 凯铭投资 | 是 | 580,000 | 0.72% | 0.14% | 2023/9/26 | 2025/3/25 | 招商证券股份有限公司 | 2、股东股份累计质押情况 截至公告披露日，凯铭投资及其一致行动人浙江贝成投资管理合伙企业（有限合伙） （以下简称 ...

1、凯铭投资股份新增质押情况 证券代码：300558 证券简称：贝达药业 公告编号：2025-013 贝达药业股份有限公司 关于股东股份质押变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）今日接到股东宁波凯铭投资管理合伙企业 （有限合伙）（以下简称"凯铭投资"）函告，获悉凯铭投资持有本公司的部分股份发生质 押变动，现将具体情况公告如下： 一、股东股份质押基本情况 3、截至本公告披露日，公司控股股东及其一致行动人不存在非经营性资金占用、违规担 保等侵害上市公司利益的情形； 4、截至本公告披露日，公司控股股东及其一致行动人的股份质押事项不会对上市公司生 产经营、公司治理等产生重大影响，本次质押变动不涉及业绩补偿义务。目前所质押的股份 不存在平仓风险或被强制过户风险，质押总体风险处于可控水平，不会出现因股份质押风险 致使公司实际控制权发生变更的情形。 | | 是否为控 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- ...